225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
暂无分享,去创建一个
F. Mottaghy | U. Haberkorn | F. Giesel | C. Kratochwil | K. Kopka | C. Apostolidis | F. Bruchertseifer | F. Verburg | A. Morgenstern | Mirjam Weis
[1] U. Haberkorn,et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.
[2] U. Haberkorn,et al. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. , 2016, Journal of medicinal chemistry.
[3] R. Fimmers,et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.
[4] E. Demirci,et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[5] U. Haberkorn,et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[6] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[7] U. Haberkorn,et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[8] RubiniGiuseppe,et al. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. , 2014 .
[9] J. Ullmann,et al. 225Ac and 223Ra production via 800 MeV proton irradiation of natural thorium targets. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[10] J. Ullmann,et al. 225-Ac and 223-Ra Production via 800 MeV Proton Irradiation of Natural Thorium Target , 2012, 1204.2299.
[11] B. Wessels,et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.
[12] C. Apostolidis,et al. An Improved Method for the Production of Ac‐225/Bi‐213 from Th‐229 for Targeted Alpha Therapy , 2007 .
[13] C. Apostolidis,et al. Production of Ac-225 from Th-229 for targeted alpha therapy. , 2005, Analytical chemistry.
[14] C. Apostolidis,et al. Cyclotron production of Ac-225 for targeted alpha therapy. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[15] J. Humm,et al. Targeted α particle immunotherapy for myeloid leukemia , 2002 .
[16] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[17] M. Andreeff,et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] U. Haberkorn,et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Giuseppe Rubini,et al. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. , 2014, Cancer biotherapy & radiopharmaceuticals.
[20] J. Humm,et al. Targeted alpha particle immunotherapy for myeloid leukemia. , 2002, Blood.